Close

BIO Written Testimony for House Ways and Means Hearing on Expired Tax Provisions

BIO supports a seamless multi-year extension for the Second Generation Biofuel Producer Tax Credit; Special Depreciation Allowance for Second Generation Biofuel Plant Property; Biodiesel and Renewable Diesel Fuels Credit; and the Alternative Fuel Vehicle Refueling Property, which expired at the end of 2017. BIO also supports the extension and expansion of the tax code to include the Qualifying Renewable Chemical Production or Investment Tax Credit and Master Limited Partnerships (MLP) to advanced biofuel and renewable chemicals.

Oregon Governor Signs Misleading Drug Pricing Bill

BIO regrets signing of misleading drug pricing and reporting bill by Oregon Governor Brown, as it will fail to provide patients the lower drug costs they were promised

BIO is Now Accepting Nominations for the 2018 Rosalind Franklin Award

Washington, D.C. (March 13, 2018) - Each year, the Biotechnology Innovation Organization (BIO) presents the Rosalind Franklin Award for Leadership in Industrial Biotechnology to an outstanding woman in the industrial biotechnology sector who has made significant contributions to the advancement of the biobased economy and biotech innovation. BIO is now accepting nominations for the 2018 Rosalind Franklin Award. The award will be presented at the 2018 World Congress on Industrial Biotechnology in Philadelphia at the Pennsylvania Convention Center from July 16-19, 2018. The deadline to submit nominations is March 28, 2018. 

International Council of Biotech Associations Launches New Website

Washington, D.C. (March 12, 2018) – The International Council of Biotech Associations (ICBA) today announced the launch of

GREENER Fuels Act Would Undermine Investment in Advanced Biofuels, BIO Says

BIO voiced its opposition to the GREENER Fuels Act, introduced by Sen. Tom Udall (D-NM) and Rep. Peter Welch (D-VT), because it would revise the Renewable Fuel Standard (RFS) in way that will chill investment in advanced biofuel.

BIO Submits Comments Re: CY 2019 Medicare Advantage and Part D Call Letter

BIO supports CMS’s commitment to improving the quality and delivery of care in the MA and Part D programs. We believe it is critically important to ensure that policies in these programs advance patient access to timely and appropriate treatment, particularly for prescription drugs and vaccines. To that end, we provide comments in the following areas: The specialty tier eligibility cost threshold should be increased for 2019 and in future years and the exceptions process expanded to ensure that the specialty tier does not discriminate against vulnerable beneficiaries;  Co-insurance in the Part D non-preferred drug tier can unduly limit access to care for patients with severe and complex diseases;  Increased enforcement of nondiscrimination should be used when evaluating benefit design in the MA and Part D programs;  Access to innovative treatment options for pain and addiction should be prioritized as a part of addressing opioid overutilization in MA Part D plans;  MA and Part D plans should prioritize and increase access to vaccinations for Medicare beneficiaries;  The timeframes and processes for formulary updates should support the inclusion of new therapies;  Drug tier labels should be accurately reflective of the tier’s composition.  The inclusion of prescription drug costs in Medicare advantage uniformity flexibility should provide patient access to the most appropriate treatment;  Additional flexibility in design of maximum out-of-pocket costs should be considered to assist beneficiaries;  The availability of suitable plan offerings should be increased through removal of the meaningful difference requirements;      Additions to the Star Ratings are critical to accurate assessment of patient care quality; and  Efforts to expand coverage for certain subsets of products MA-PD plans should focus across all drugs offered under the Part D program.

BIO Applauds Introduction of the Ensuring the Value of the 340B Program Act of 2018

Washington, DC (March 1, 2018) – BIO President and CEO Jim Greenwood issued the following statement today regarding the introduction by Senator Charles Grassley of S. 2453, the Ensuring the Value of the 340B Program Act of 2018:

BIO Selects Des Moines as Venue for the 2019 BIO World Congress on Industrial Biotechnology

The Biotechnology Innovation Organization (BIO) today announced the selection of Des Moines, Iowa, as the location for the 2019 BIO World Congress on Industrial Biotechnology. The event will be held July 8-11, 2019 and it will host industry executives, investors, policy makers and academics from around the world and will feature the BIO One-on-One Partnering™ system.

Orphan Drugs: BIO Comments on FDA Draft Guidance Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases

Re: Docket No. FDA-2017-D-6380: Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases

...

PFDD: BIO Comments on FDA Public Workshop on Patient-Focused Drug Development: Guidance 1- Collecting Comprehensive and Representative Input

Re: Docket No. FDA–2017-N-5896: Public Workshop: Patient-Focused Drug Development: Guidance 1- Collecting Comprehensive and Representative Input

...